These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1380754)

  • 1. [Value of prostate-specific antigen as prognostic factor of metastatic cancer of the prostate].
    Morote Robles J; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
    Actas Urol Esp; 1992 May; 16(5):394-7. PubMed ID: 1380754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
    Barak M; Mecz Y; Lurie A; Gruener N
    J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports].
    Bordes M; Brunet-Lecomte P; Dusserre P; Dusserre-Guion L; Michiels-Marzais D; Morlevat F; Peny J; Roignot P; Colas JM; Ferry N
    Ann Urol (Paris); 1989; 23(4):295-300. PubMed ID: 2480077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical use of the prostate-specific antigen in patients with prostatic cancer].
    Matveev BP; Sokolov AV; Bukharkin BV; Ledian KM; Tilk AE; Makarova GV
    Urol Nefrol (Mosk); 1991; (4):8-12. PubMed ID: 1719686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F; Zambolin T; Bonora R; Panteghini M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
    Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
    Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
    Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.